tumour contamination and ease of acquisition. Although superiority in terms of an anti-tumour effect has yet to be demonstrated, the short-term clinical benefits of PBPC have Increasingly, PBPC instead of BM are used for autologous transplantation. Limited data exist on the economic led to its widespread adoption in autologous transplantation. effects of this change. Using a resource-based utilization model we prospectively determined the costs of 48 autoWith the increased utilization of PBPC has come the concern that the incremental acquisition costs of PBPC may logous transplants (eight BM, 17 BM + PBPC, 23 PBPC), isolating the post-reinfusion period (day 0 to not be offset by cost savings related to quicker engraftment and shorter hospital stays. This concern has been partially discharge) to better determine the effect of the rescue product. Length of stay post-reinfusion was significantly addressed in a series of retrospective studies, performed in heterogeneous patient populations, 3-6 and more recently shorter in patients receiving PBPC (median 13 days) or BM + PBPC (median 14 days) vs BM alone (median 20 prospectively. 7 Clarifying the economic benefits of PBPC however, requires that the costs that are dependent on the days) (P Ͻ 0.01). Accordingly, transplant admission costs were less in the PBPC groups (PBPC $22 089, PBPC component (ie acquisition costs and costs from day of transplant forward) are separated from the total costs of BM + PBPC $23 179) vs the BM alone group ($32 289) (P Ͻ 0.05). Rescue product acquisition costs were higher the transplant. These total costs may vary significantly due to other factors such as the conditioning regimen, which is for PBPC (range $3439-$5157) vs BM ($2766) but these costs were offset by the more rapid recovery of patients chosen based on the disease being treated, that are independent of the rescue product. receiving PBPC. Overall transplant costs depend on the conditioning regimen with a 10-fold cost variation
for non-Hodgkin's lymphoma (NHL), Hodgkin's lymthat could be met as an out-patient (ie requiring no more than two transfusions per week) and no other medical probphoma (HD), or multiple myeloma (MM) unresponsive to conventional therapy were eligible for inclusion in the lems requiring them to remain in hospital. Supportive care and discharge practices were consistent throughout the study. Bone marrow (BM) had previously been collected and cryopreserved following recovery from salvage chemoperiod of analysis. therapy (DHAP, mini-BEAM or cyclophosphamide 4.5 g/m 2 ). Similarly, peripheral blood progenitor cells (PBPC) were collected during daily ϫ 2 or 3, 10-l leukaphereses on a Cobe Spectra (Cobe Laboratories, Lakewood, CO, USA)
Cost analysis following mobilization with the above salvage chemotherapy regimens and G-CSF (Neupogen; Amgen, Thou- As the purpose of the analysis was to determine the cost implications of using PBPC vs BM in varied approaches sand Oaks, CA, USA) ෂ5 g/kg/day s.c. ϫ 9 days. As part of a phase 2 trial, several patients' BM or PBPC were CD34 to autologous transplantation, those aspects related to the transplant that are dependent on the rescue product or selected using the Ceprate system (CellPro, Bothell, WA, USA). The type of rescue product used in any individual potentially influenced by the rescue product are included. The transplant-related costs were determined for each patient reflects the progressive shift in practice at our institution from using BM alone to BM and PBPC in a tranpatient using a model developed at our institution as previously reported. 8 Costs were determined from the perspecsition period to PBPC alone as we developed confidence in the reconstitutive potential of PBPC. None of the BMtive of the payer agency (Ministry of Health for the province of Ontario). For this analysis, the components of the only patients had PBPC collected, while some PBPC-only transplant patients had a back-up marrow stored. Patients transplant process for which costs were determined include BM and PBPC collection, processing and storage, the transreceived PBPC-only transplants if the CD34 + cell count of the PBPC product was Ͼ1 ϫ 10 6 /kg patient weight.
plant admission, blood product support and professional fees. Other aspects of the salvage programme including Patients were conditioned pre-transplant with one of several high-dose regimens depending on their diagnosis and insertion of the Hickman line, salvage therapy admissions, pretransplant pulmonary function testing and cardiac prior treatment history. Most patients received CBV for HD or MelVP16TBI 9 for low-grade NHL. Patients with inter-MUGA scans are common to all groups (BM, BM + PBPC and PBPC) and unrelated to the actual transplant admission mediate-grade NHL received either regimen. Patients with multiple myeloma were conditioned with BUCY regimens so they are not included in this analysis. The cost of G-CSF used in mobilizing PBPC is included in the PBPC (BUCY ± TBI 500 cGy). All patients received G-CSF (ෂ5 g/kg/day s.c.) following reinfusion of autologous BM acquisition costs as G-CSF is not routinely used at our centre following salvage chemotherapy. and/or PBPC until the absolute neutrophil count (ANC) was Ͼ0.5 ϫ 10 9 /l. Actual G-CSF dose (300 or 480 g/day) was Hospital-related costs were determined using actual patient resource utilization as captured by the hospital's onbased on the two vial sizes of Neupogen commercially available and an attempt to give ෂ5 g/kg patient weight.
line accounting system, the Transition System 1. This system captures all patient-specific direct (nurses etc) and Patients were nursed on a standard hospital ward with HEPA filters but without laminar airflow rooms. Platelets indirect (overhead, laboratory technicians, supplies etc) resources utilized in hospital under a number of cost centres (random or single donor) were transfused to maintain a platelet count Ͼ20 ϫ 10 9 /l or if febrile (T°Ͼ 38°C) (nursing, pharmacy, laboratories etc). BM and PBPC are collected at our institution and are processed at the Ottawa Ͼ30 ϫ 10 9 /l and packed red blood cells (PRBC) were given to maintain a hemoglobin (Hb) Ͼ90 g/l. Blood proCentre of the Canadian Red Cross (CRC). The costs for collection, processing and storage of BM and PBPC were ducts were irradiated. Twice weekly trimethoprim-sulfamethoxazole was given for pneumocystis pneumonia prophydetermined from both the Transition System 1 and by determining attributable costs for each product processed at laxis starting from admission. Patients received acyclovir for HSV prophylaxis. Whenever possible acyclovir was the CRC. During the time of this study, within the Canadian Health Care system, blood products were supplied to hospigiven as the oral preparation. No other prophylactic antibiotics or anti-fungals were used routinely. Febrile neutrotals by the CRC free of charge. For purposes of the analysis, costs for blood products were determined as the per penia (T°Ͼ38°C and ANC Ͻ0.5 ϫ 10 9 /l) was treated with either a combination of piperacillin and tobramycin or sinunit cost for the CRC to supply these products multiplied by the number of units of each type of blood product utilgle agent therapy with a third generation cephalosporin. Empiric vancomycin and amphotericin B were added after ized per patient. Appendix 1 lists the unit cost for several of these blood products. Professional fees were determined 3 to 5 days and 5 to 7 days, respectively, for persistent fever despite the use of broad spectrum antibiotics. Antimicrobial based on the provincial fee schedule for professional services supplied, including direct patient care and related therapy was further modified based on culture results. Antimicrobials were continued until neutrophil engraftment costs such as reporting of radiographs etc. For the transplant stay, costs were collected for each patient from day (ANC Ͼ0.5 ϫ 10 9 /l) and defervescence. Patients unable to maintain an adequate oral caloric intake were fed whenever of admission to day of discharge. The costs of CD34 + selection carried out as part of a possible via a nasogastric tube, or if necessary with total parenteral nutrition. Patients were discharged from the hosseparate phase 2 trial are not included as this was not routine care during the study period. In addition, CD34 + selecpital once they were afebrile, ambulatory, had neutrophil engraftment, adequate oral intake, transfusion requirements tion has not been shown to accelerate neutrophil or platelet 891 and services were those of our hospital except for G-CSF.
Age (years)
The unit cost of G-CSF used was the manufacturer's list cost of transplant admission) was done using an analysis ing PBPC and BM alone in terms of neutrophil and platelet engraftment, days on G-CSF, duration of hospital stay, and days from transplant to discharge (Table 2 ). In all cases the Results groups receiving PBPC (BM + PBPC or PBPC alone) had superior results. For example, the median number of days Forty-eight patients underwent autologous transplantation to neutrophils Ͼ0.5 × 10 9 /l was 12.5, 10 and 9 in the BM, and received all their care at our institution during the study BM + PBPC, PBPC groups respectively (P = 0.02). There period. Four others were not included because they were was no difference, however, in time to neutrophil or platelet transferred back to another centre on day +1 as is our pracengraftment, length of hospital stay, days from transplant tice. As a result cost data were not available for this group.
to discharge, days of G-CSF or days febrile between the Of the 48 patients, eight received BM only, 17 received groups receiving PBPC and BM or PBPC alone (Table 2) . BM + PBPC and 23 PBPC alone. Table 1 summarizes the The number of days to deliver each conditioning regimen age, sex, diagnosis and conditioning for these three groups.
varied from 6 to 8 (Table 3) . As a result, the number of There was no difference in median age of the three groups. days in hospital from day 0, the day of the rescue product The proportion of patients having each of the diagnoses is infusion to discharge better reflects the short-term clinical not balanced among the groups as the study was not randifferences between the rescue products. The time from resdomized but an analysis of our practice over a period of cue product infusion to discharge was 20, 14 and 13 days time. Similarly, as the conditioning regimens are chosen in the BM alone, BM + PBPC and PBPC alone groups, based on the disease and not the rescue product, the prorespectively. Again there was a clinical and statistical difportion of patients receiving different conditioning regiference in favour of the groups receiving PBPC vs the mens is not balanced among the groups. As all patients group receiving BM alone (P = 0.005) ( Table 2 ). The benereceived high-dose therapy and the diagnosis is not fit of PBPC in shortening hospital stay due to more rapid expected to affect post-transplant recovery costs we felt engraftment and clinical recovery although evident by the comparisons of the groups were valid. The post-reinfusion shorter median time from transplant to discharge is better G-CSF doses in g/kg patient weight were 4.6, 4.5, 4.0 in represented by looking at the probability of discharge postthe BM, BM + PBPC, PBPC alone groups, respectively, transplant in the BM alone vs PBPC (Figure 1 ) where the and were not statistically different (P = 0.33).
effect of outliers can be seen. Blood product requirements were low and similar in all three groups. There was a trend to lower numbers of platelet transfusions in the PBPC groups (five single donor unit Hematological recovery and morbidity equivalents) compared to the BM alone group (eight single donor unit equivalents) but this was not significant. There were clinically and statistically significant differences in pairwise comparisons between the groups receiv- Table 2 Outcome rescue product (Table 4) mens (Table 3 ). The effect of the varying conditioning regimens on overall costs relates both to the number of days over which they are administered and the unit costs of the component chemotherapeutic agents and TBI (Table 3 ). The most expensive regimens by several-fold are those containing Table 3 Administration days and costs of conditioning regimens etoposide while the least expensive conditioning regimen is standard BUCY ($563 per course).
Days a MD fees Pharmacy costs Total b
The cost of the rescue product depends on multiple fac- related costs of the harvest procedure, professional fees of variable and depend on the number of days and dose of G-CSF used in mobilizing, the weight of the patient, the number of phereses performed to collect an adequate number of groups, the conditioning regimen made up the largest proportion of the pharmacy costs (approximately 45%), the PBPC and the costs of processing and storing the collected product. In order to reflect these variables we constructed post-transplant G-CSF contributed 17% and the remainder was due to other aspects of supportive care including antia series of modeled results (Table 6 ) which consist of the transplant costs without the stem cell product as reported emetics and antibiotics. above plus the acquisition costs for the different rescue products (Table 5 ) based on G-CSF dose and days of phereses. The costs of the rescue product range from $2766 for BM alone to $5157 for 9 days of 480 g G-CSF and three pherDiscussion eses. The use of these together would result in a rescue product costing $7923. With all the rescue products mod-
The main purpose of our study was to determine clinical and economic effects of varied approaches to autologous eled, the additional acquisition cost of PBPC is less than the savings they realize through faster engraftment and shorter transplantation following the introduction of PBPC into practice at an average-sized Canadian transplant prohospital stays (Table 6) .
A breakdown of the transplant stay by cost centre is gramme. While the efficacy of auto-PBSC has been established, the cost-effectiveness of PBSC with their higher depicted in Figure 2 . In all three groups (BM, BM + PBPC, PBPC) even though there were differences between the acquisition costs remains unresolved compared to BM. There are several aspects of our study that are a result of total cost of the transplant admission, the proportion that was attributable to each cost centre (nursing, pharmacy, our programme being in Canada and our institution having an on-line resource utilization based accounting system. laboratories etc) was the same. The combination of nursing and pharmacy accounted for approximately 74% of the The main benefit to our study is that the difficulty of differentiating costs from charges 10 as occurs in many American transplant stay costs in all three groups. Similarly, for all Table 6 Modeled costs of autologous transplantation based on rescue product 0  25 349  35 055  36 495  300  yes  2  23 911  29 383  35 878  300  yes  3  24 926  30 398  36 893  480  yes  2  24 616  30 088  36 583  480  yes  3  25 630  31 102  37 597  300  no  2  11 988  25 528  38 496  300  no  3  13 002  26 542  39 510  480  no  2  12 692  26 232  39 200  480  no  3  13 706  27 246  40 214 a All values in Canadian dollars. Costs = rescue product acquisition costs (Table 5 ) + transplant admission costs (Table 4) . BM = bone marrow; PBPC = peripheral blood progenitor cells. studies does not exist within the Canadian Health care sysnormal levels. Similarly, while total transplant costs are a useful crude estimate of the cost benefits of PBPC, varitem. Canadian hospitals function primarily within a single payer agency system and function as non-profit institutions.
ations in pre-reinfusion practice may significantly influence total costs and bias the results in favour of or against a The payer agency, the Ministry of Health for Ontario, pays for services provided to in-patients. Although supplemental particular approach. In our study, conditioning costs varied significantly depending on the regimen chosen. This was insurance is common for patients, it does not affect what the Ministry of Health pays the hospitals for in-patient serin part due to the number of days over which a particular regimen is given, but more significantly due to the differvices. The same applies to physician billings. Extra billing, the charging of fees above the provincial schedule within ence in cost of the different chemotherapeutic agents. For example at our institution, MelVP16TBI ($6701) costs the Ontario Health Insurance Plan, is prohibited.
The use of an on-line resource utilization based accountmore than 10 times as much as BUCY ($563). As the conditioning regimen is chosen based on the diagnosis and not ing system enables us to determine more accurately what an individual stay costs the health care system. Finally, to the rescue product, these costs should be isolated when performing a cost analysis of PBPC vs BM. In addition, until a large extent the Canadian health care system is less driven by medical-legal concerns than its American counterpart.
there is convincing evidence of superiority of one regimen over another, the choice of conditioning regimen remains As a result, the practice pattern with regards to tests and supportive care is less exhaustive. Nonetheless, although an opportunity for cost reduction at centres needing to control total programme costs. our results in total dollars are significantly less than results reported from many American institutions, and this is in Although the transplant admission costs as reported here and elsewhere [3] [4] [5] [6] [7] are fairly homogeneous with PBPC, the part due to differences in practice style, the use of unit costs and resource utilization based costs should enable other cost of the rescue product varies significantly depending on what is used. As it is not possible always to use the same institutions to compare their practice patterns and unit costs with our results. Precise inter-institutional or international product (eg inability to harvest BM if prior pelvic irradiation) and patient size influences rescue product comparisons of transplant costs, however, remains problematic due to differences in accounting practices and overacquisition costs, we modeled the cost of the rescue product based on differing numbers of phereses, vial size of G-CSF, head among centres. Furthermore, as competition among transplant centres in America increasingly includes cost and whether PBPC, BM or both were utilized. In all models, the acquisition costs of PBPC in the rescue product along with quality, significant reductions in transplantrelated charges and costs are beginning to be realized.
($3439-$5157) were offset by the savings realized through their use as a result of faster haematological recovery postThe clinical benefits of shorter engraftment times previously reported with PBPC have been confirmed in our transplantation. The use of such modeling allows centres beginning a transplant programme or centres analyzing the cohort of patients. Initial concerns that PBPC may not result in sustained engraftment led to their use as an adjunct costs of their programme to estimate for a population of patients what the costs of the various approaches would be to BM in autologous transplantation. Experience, however, indicates that to date this concern is unfounded. This has better than assigning one cost per transplant value. Obviously, in some situations such as failure to mobilize, the led to the use of PBPC alone in many centres. Within our study the use of BM in addition to PBPC was not associated cost of PBPC collection would not be offset by their use but this represents a small fraction of patients and could be with any clinical advantage but an additional cost of approximately $2800 per transplant. If no back-up BM is included in a programme's overall cost model. While other aspects of care will influence the overall required, this cost can be eliminated. Another advantage to PBPC is reflected in the early data indicating that patients costs of the transplant, the costs of the transplant admission are driven by nursing and pharmacy. In our study, indewho have experienced donating both generally prefer donating PBPC over BM. 9 pendent of the approach used, nursing accounted for approximately 30% of transplant admission costs while As indicated earlier, to best determine the impact of PBPC it is necessary to isolate clinical effects and costs pharmacy was ෂ45%. Of pharmacy costs, conditioning was ෂ45% and post-transplant G-CSF ෂ20% in the BM groups that are attributable to their use. This is best represented by the intermediate outcome time from reinfusion to disand ෂ15% in the PBPC groups. All other aspects of pharmacy accounted for ෂ25% of transplant admission costs. charge. In our study the time from reinfusion (day 0) to discharge was significantly shorter, approximately 7 days Further efforts at making auto-transplantation more economical will have to look at ways of reducing those two in the PBPC groups. The time difference was greater than simply the difference in the number of days to neutrophil components by moving transplants to the out-patient setting as is now the practice at our institution, and as before, (ANC, 0.5 ϫ 10 9 /l) or platelet (20 ϫ 10 9 /l) engraftment. The advantage seen in time to discharge with PBPC is more potentially reconsidering what conditioning regimen is being used. Conversely, other aspects of long-term outcome likely related to the rapid rise of neutrophils to normal or supranormal levels seen with PBPC compared to BM and may adversely affect short-term choices if delayed toxicities are more common or serious with the regimen having not simply the more rapid achievement of 0.5 × 10 9 /l neutrophils. Resolution of fever, infections and probably mucothe least up-front costs. Future economic analyses will need to consider these variables as more data become available. sitis occur with less variation following autologous transplantation with PBPC compared to BM where some
Comparison of our results with those published recently by Smith et al 7 highlights both the difficulties of inter-instipatients have slow clinical recovery with neutrophil counts at or around 0.5 × 10 9 /l for many days prior to returning to tutional comparisons and the overall similarity of results when contrasting BMT and PBPCT. The first difference is logous transplantation remains a cost-effective therapeutic option for many patients. in the currency reported with our costs (1994 Can$) equal to ෂ$0.75 1995 US. More importantly, significant management practice differences between the two studies including neutrophil level for stopping G-CSF, discharge criteria, use
